Landscape Capital Management L.L.C. Invests $1.77 Million in West Pharmaceutical Services, Inc. $WST

Landscape Capital Management L.L.C. acquired a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the fourth quarter, Holdings Channel.com reports. The institutional investor acquired 6,431 shares of the medical instruments supplier’s stock, valued at approximately $1,769,000.

A number of other institutional investors and hedge funds have also modified their holdings of WST. Elyxium Wealth LLC acquired a new stake in shares of West Pharmaceutical Services in the fourth quarter worth $25,000. CYBER HORNET ETFs LLC acquired a new position in West Pharmaceutical Services during the 2nd quarter valued at $25,000. Private Trust Co. NA lifted its holdings in shares of West Pharmaceutical Services by 156.4% during the 4th quarter. Private Trust Co. NA now owns 100 shares of the medical instruments supplier’s stock worth $28,000 after acquiring an additional 61 shares during the period. International Assets Investment Management LLC bought a new position in shares of West Pharmaceutical Services during the 4th quarter worth about $31,000. Finally, Torren Management LLC bought a new stake in shares of West Pharmaceutical Services in the 4th quarter worth about $34,000. 93.90% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Morgan Stanley increased their price objective on shares of West Pharmaceutical Services from $315.00 to $325.00 and gave the stock an “equal weight” rating in a report on Friday, May 29th. Evercore reaffirmed an “outperform” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Barclays raised shares of West Pharmaceutical Services from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $310.00 to $400.00 in a research note on Tuesday, June 9th. Citigroup reaffirmed a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, April 24th. Finally, Zacks Research raised shares of West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $340.09.

Insiders Place Their Bets

In other news, CAO Chad Winters sold 896 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $300.67, for a total value of $269,400.32. Following the sale, the chief accounting officer owned 1,523 shares of the company’s stock, valued at $457,920.41. The trade was a 37.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Annette F. Favorite sold 2,817 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $305.20, for a total transaction of $859,748.40. Following the completion of the sale, the vice president directly owned 16,828 shares in the company, valued at approximately $5,135,905.60. This represents a 14.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.60% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $330.89 on Tuesday. The firm’s 50 day moving average price is $300.48 and its two-hundred day moving average price is $271.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.04 and a current ratio of 2.71. The firm has a market cap of $23.38 billion, a P/E ratio of 44.24, a PEG ratio of 2.75 and a beta of 1.18. West Pharmaceutical Services, Inc. has a twelve month low of $206.80 and a twelve month high of $336.82.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, April 23rd. The medical instruments supplier reported $2.13 EPS for the quarter, topping analysts’ consensus estimates of $1.68 by $0.45. The business had revenue of $844.90 million for the quarter, compared to analyst estimates of $779.68 million. West Pharmaceutical Services had a net margin of 16.85% and a return on equity of 19.03%. The firm’s revenue for the quarter was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.45 earnings per share. West Pharmaceutical Services has set its FY 2026 guidance at 8.400-8.750 EPS and its Q2 2026 guidance at 2.050-2.120 EPS. On average, analysts forecast that West Pharmaceutical Services, Inc. will post 8.6 EPS for the current fiscal year.

West Pharmaceutical Services declared that its board has authorized a stock repurchase program on Tuesday, February 17th that permits the company to buyback $1.00 billion in outstanding shares. This buyback authorization permits the medical instruments supplier to purchase up to 5.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.